MucoLife awarded SEK 500,000 for Sweden–UK COPD research partnership
The Vinnova grant supports a shared preclinical strategy for inhaled peptide therapies and preparations for regulatory advice.
Vinnova awarded MucoLife Therapeutics SEK 500,000 for its MUCO-Bridge project in a funding decision dated September 22, 2026. The project builds a Sweden–UK partnership around inhaled peptide therapies for chronic obstructive pulmonary disease.
The work will develop a joint preclinical strategy, prepare a request for regulatory scientific advice, and establish intellectual property and data-sharing arrangements. These steps support MucoLife’s development of investigational treatments designed to dissolve airway mucus plugs.
Use of funds
Build a Sweden–UK partnership and preclinical strategy for inhaled peptide therapies addressing COPD
Prepare regulatory scientific advice and joint intellectual property and data-sharing arrangements